Search
Dianthus Therapeutics Inc
DNTHAdd to Watchlist
106.920USD
-5.720-5.08%
Close 07-31 16:00（ET）Quotes delayed by 15 min
5.84BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Dianthus Therapeutics Inc is 9.00, ranking 16 out of 385 in the Biotechnology & Medical Research industry. The average price target is 65.00, with a high of 100.00 and a low of 46.00.
Analyst Rating
Based on
16
analysts
Strong Buy
Current Rating
127.692
Target Price
+22.67%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Dianthus Therapeutics Inc
DNTH
16
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Dianthus Therapeutics Inc's expected revenue for the next quarter?
Dianthus Therapeutics Inc's expected revenue is 258.58K.
What is Dianthus Therapeutics Inc's price target?
Analysts forecast that Dianthus Therapeutics Inc's price target is USD 65.00, with the highest forecast at USD 100.00 and the lowest forecast at USD 46.00.
How have Dianthus Therapeutics IncDNTH's recent earnings per share performed?
The market expectation was USD -0.85, while Dianthus Therapeutics IncDNTH's earnings per share (EPS) for the previous quarter was USD -1.43. EPS for the next quarter is expected at USD -0.86.
What is the analyst rating for Dianthus Therapeutics Inc?
Based on the ratings of Dianthus Therapeutics Inc's stock from 16 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.